The genomic landscape of fibrolamellar hepatocellular carcinoma: Whole genome sequencing of ten patients

Oncotarget

Volumn 6, Issue 2, 2015, Pages 755-770

  Darcy, David G ^a,b   Chiaroni Clarke, Rachel ^a   Murphy, Jennifer M ^a,b   Honeyman, Joshua N ^a,b   Bhanot, Umesh ^b   LaQuaglia, Michael P ^b   Simon, Sanford M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Fibrolamellar; Genome; Hepatocellular carcinoma; Sequencing

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHROMOSOME 19; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; INDEL MUTATION; LIVER CANCER; LIVER CARCINOGENESIS; MALE; MIDDLE AGED; MUTATION RATE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; WHOLE GENOME SEQUENCING; YOUNG ADULT; GENETICS; GENOMICS; HUMAN GENOME; LIVER CELL CARCINOMA; LIVER TUMOR;

TUMOR MARKER;

ADOLESCENT; ADULT; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; GENOME, HUMAN; GENOMICS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84921741610     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2712     Document Type: Article

References (64)

1. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980 Jul 15;46:372-9.
2. Meyers RL. Tumors of the liver in children. Surg Oncol. 2007 Nov; 16:195-203.
3. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988 Jul; 19:784-94.
4. Paradinas FJ, Melia WM, Wilkinson ML, Portmann B, Johnson PJ, Murray-Lyon IM, Williams R. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). 2025 Sep; 11982/09/25:840-2.
5. Weeda VB, Murawski M, McCabe AJ, Maibach R, Brugières L, Roebuck D, Fabre M, Zimmermann A, Otte JB, Sullivan M, Perilongo G, Childs M, Brock P, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma-Results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer. 2013 Aug; 49:2698-704.
6. Mayo SC, Mavros MN, Nathan H, Cosgrove D, Herman JM, Kamel I, Anders RA, Pawlik TM. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. Journal of the American College of Surgeons. 2014 Feb; 218:196-205.
7. Njei B, Konjeti VR, Ditah I. Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Gastrointest Cancer Res. 2014 Mar; 7:49-54.
8. Collier NA, Weinbren K, Bloom SR, Lee YC, Hodgson HJ, Blumgart LH. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet. 1984 Mar; 10;1:538-40.
9. Ehrenfried JA, Zhou Z, Thompson JC, Evers BM. Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma. Ann Surg. 1994 Oct; 220:484-9-discussion 489-91.
10. Wheeler K, Pritchard J, Luck W, Rossiter M. Transcobalamin I as a "marker" for fibrolamellar hepatoma. Med Pediatr Oncol. 1986; 1986/01/01:227-9.
11. Orsatti G, Greenberg PD, Rolfes DB, Ishak KG, Paronetto F. DNA ploidy of fibrolamellar hepatocellular carcinoma by image analysis. Hum Pathol. 1994/09/01:936-9.
12. Wilkens L, Bredt M, Flemming P, Kubicka S, Klempnauer J, Kreipe H. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol [Internet]. 2000 Dec; 114:867-74.
13. Lowichik A, Schneider NR, Tonk V, Ansari MQ, Timmons CF. Report of a complex karyotype in recurrent metastatic fibrolamellar hepatocellular carcinoma and a review of hepatocellular carcinoma cytogenetics. Cancer Genet Cytogenet. 1996 Jun; 1996/06/01:170-4.
14. Ding SF, Delhanty JDA, Bowles L, Dooley JS, Wood CB, Habib NA. Infrequent chromosome allele loss in fibrolamellar carcinoma. Br J Cancer. [Internet]. 1993 Feb; 67:244-6.
15. Xu YH, Peters RL. Mitochondrial abnormalities in hepatocytes adjacent to fibrolamellar hepatocellular carcinoma. J Tongji Med Univ. 1986; 6:26-30.
16. Vivekanandan P, Daniel H, Yeh MM, Torbenson M. Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas. Mod Pathol. 2010/03/17:790-8.
17. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim IIP, Gleason CE, Murphy JM, Rosenberg BR, Teegan L, Takacs CN, Botero S, Belote R, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. (New York, NY). 2014 Feb 28; 343:1010-4.
18. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, Mooney TB, Callaway MB, Dooling D, Mardis ER, Wilson RK, Ding L. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 2012 Aug; 22:1589-98.
19. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014 Jan; 42:D199-205.
20. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. Nature. 2013 Jun 16;499:214-8.
21. Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012 Sep 15; 28:i333-i339.
22. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956 Feb; 91:168-86.
23. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003 Apr 15; 2003/04/04:2006-12.
24. Malouf GG, Brugieres L, Le Deley M-C, Faivre S, Fabre M, Paradis V, Aerts I, Le Tourneau C, Dreyer C, Branchereau S, Belghiti J, Raymond E. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer. 2012 Mar 13; 2012/03/15:4981-90.
25. Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma. Oncology. 2013 Sep 19; 85:197-203.
26. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol [Internet]. 2010 Sep; 23:1180-90.
27. Patonai A, Erdelyi-Belle B, Korompay A, Somoracz A, Torzsok P, Kovalszky I, Barbai T, Raso E, Lotz G, Schaff Z, Kiss A. Molecular characteristics of fibrolamellar hepatocellular carcinoma. Pathol Oncol Res. [Internet]. 2012 Aug 8; 19:63-70.
28. Buckley AF, Burgart LJ, Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006/03/28:410-4.
29. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science (New York, NY). 2013 Mar 29; 339:1546-58.
30. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009 Dec; 9:874-85.
31. Carraway KL, Theodoropoulos G, Kozloski GA, Carothers Carraway CA. Muc4/MUC4 functions and regulation in cancer. Future Oncol. 2009 Dec; 5:1631-40.
32. Albrecht H, Carraway KL. MUC1 and MUC4: switching the emphasis from large to small. Cancer Biother Radiopharm. 2011 Jun; 26:261-71.
33. Guo X, Zheng S, Dang H, Pace RG, Stonebraker JR, Jones CD, Boellmann F, Yuan G, Haridass P, Fedrigo O, Corcoran DL, Seibold MA, Ranade SS, et al. Genome Reference and Sequence Variation in the Large Repetitive Central Exon of Human MUC5AC. Am J Respir Cell Mol Biol. 2014 Jan; 50:223-32. doi: 10.1165/rcmb.2013-0235OC.
34. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008 Apr; Chapter 10:Unit 10.11.
35. Stamatoyannopoulos JA, Adzhubei I, Thurman RE, Kryukov GV, Mirkin SM, Sunyaev SR. Human mutation rate associated with DNA replication timing. Nature Genetics. 2009 Apr; 41:393-5.
36. Chen C-L Rappailles A, Duquenne L, Huvet, M Guilbaud G, Farinelli L, Audit B, d'Aubenton-Carafa Y, Arneodo A, Hyrien O, Thermes. Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Res. 2010 Apr; 20:447-57.
37. Hashash JG, Thudi K, Malik SM. An 18-year-old woman with a 15-cm liver mass and an ammonia level of 342. Gastroenterology. 2012/09/25:1157, 1401-2.
38. Berger C, Dimant P, Hermida L, Paulin F, Pereyra M, Tejo M. [Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma]. Medicina (B Aires). 2012; 72:425-7.
39. Sethi S, Tageja N, Singh J, Arabi H, Dave M, Badheka A, Revankar S. Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma. Am J Med Sci. 2009 Dec; 338:522-4.
40. Liu H, Dong H, Robertson K, Liu C. DNA Methylation Suppresses Expression of the Urea Cycle Enzyme Carbamoyl Phosphate Synthetase 1 (CPS1) in Human Hepatocellular Carcinoma. Am J Pathol. Elsevier Inc; 2011 Feb 1; 178:652-61.
41. Wang J, Mullighan CG, Easton J, Roberts S, Heatley SL, Ma J, Rusch MC, Chen K, Harris CC, Ding L, Holmfeldt L, Payne-Turner D, Fan X, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods. 2011 Aug; 8:652-4.
42. Blake J, Riddell A, Theiss S, Gonzalez AP, Haase B, Jauch A, Janssen JWG, Ibberson D, Pavlinic D, Moog U, Benes V, Runz H. Sequencing of a patient with balanced chromosome abnormalities and neurodevelopmental disease identifies disruption of multiple high risk loci by structural variation. PLoS ONE. 2014; 9:e90894.
43. MacDonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW. The Database of Genomic Variants: a curated collection of structural variation in the human genome. Nucleic Acids Res. 2014 Jan; 42:D986-92.
44. Ward SC, Waxman S. Fibrolamellar Carcinoma: A Review with Focus on Genetics and Comparison to Other Malignant Primary Liver Tumors. Semin Liver Dis. 2011 Feb; 2011/02/24:061-70.
45. Cleary SP, Jeck WR, Zhao X, Selitsky SR. Identification of driver genes in hepatocellular carcinoma by exome sequencing-Cleary-Hepatology-Wiley Online Library. 2013.
46. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics. 2012 Jun; 44:694-8.
47. He Y, Meng X-M, Huang C, Wu B-M, Zhang L, Lv X-W, Li J. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer Lett. 2014 Mar 1; 344:20-7.
48. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006 Apr 20; 25:2537-45.
49. Nakagawa H, Shibata T. Comprehensive genome sequencing of the liver cancer genome. Cancer Lett. 2013 Nov 1; 340:234-40.
50. Sirivatanauksorn Y, Sirivatanauksorn V, Lemoine NR, Williamson RC, Davidson BR. Genomic homogeneity in fibrolamellar carcinomas. Gut. 2001 Jul; 49:82-6.
51. Li H, Ruan J, Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 2008 Nov 1; 18:1851-8.
52. Picard [Internet]. [cited 2014 Jul 23]. Available from: http://broadinstitute.github.io/picard.
53. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010 Sep; 20:1297-303.
54. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012 Mar; 22:568-76.
55. Ramos AH. Oncotator [Internet]. [cited Sept 2014 Sept 11]. Available from: http://www.broadinstitute.org/oncotator/.
56. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010 Mar 15; 26:841-2.
57. Karolchik D, Barber GP, Casper J, Clawson H, Cline MS, Diekhans M, Dreszer TR, Fujita PA, Guruvadoo L, Haeussler M, Harte RA, Heitner S, Hinrichs AS, et al. The UCSC Genome Browser database: 2014 update. Nucleic Acids Res. 2014 Jan; 42:D764-70.
58. Muramori K, Taguchi S, Taguchi T, Kohashi K, Furuya K, Tokuda K, Ishii E. High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol. [Internet]. 2011 Jun 14; 2011/05/10:e195-7.
59. Honda K, Sbisa E, Tullo A, Papeo PA, Saccone C, Poole S, Pignatelli M, Mitry RR, Ding S, Isla A, Davies A, Habib NA. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer. 1998/03/26:776-82.
60. Moinzadeh P, Breuhahn K, Stützer H, Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis. Br J Cancer. 2005 Mar 14; 92:935-41.
61. Kakar S, Chen X, Ho C, Burgart LJ, Sahai V, Dachrut S, Yabes A, Jain D, Ferrell LD. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol. Nature Publishing Group Nov 7; 2008/11/11:134-41.
62. Marchio A, Pineau P, Meddeb M, Terris B, Tiollais P, Bernheim A, Dejean A. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene. 3AD Jul 30; 2000/08/19:3733-8.
63. Terracciano L, Tornillo L. Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. Pathologica. 2003/05/29:71-82.
64. Terracciano LM, Tornillo L, Avoledo P, Schweinitz Von D, Kuhne T, Bruder E. Fibrolamellar hepatocellular carcinoma occurring 5 years after hepatocellular adenoma in a 14-year-old girl: a case report with comparative genomic hybridization analysis. Arch Pathol Lab Med. 2004/01/23: 222-6.